121 related articles for article (PubMed ID: 31699386)
1. New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.
Bertrand J; Dostálová H; Krystof V; Jorda R; Castro A; Mella J; Espinosa-Bustos C; María Zarate A; Salas CO
Bioorg Chem; 2020 Jan; 94():103361. PubMed ID: 31699386
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.
Bertrand J; Dostálová H; Kryštof V; Jorda R; Delgado T; Castro-Alvarez A; Mella J; Cabezas D; Faúndez M; Espinosa-Bustos C; Salas CO
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745866
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
[TBL] [Abstract][Full Text] [Related]
5. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
7. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Melge AR; Kumar LG; K P; Nair SV; K M; C GM
J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
[TBL] [Abstract][Full Text] [Related]
8. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker.
Pan X; Dong J; Shi Y; Shao R; Wei F; Wang J; Zhang J
Org Biomol Chem; 2015 Jul; 13(25):7050-66. PubMed ID: 26052668
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
11. New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs.
Delgado T; Veselá D; Dostálová H; Kryštof V; Vojáčková V; Jorda R; Castro A; Bertrand J; Rivera G; Faúndez M; Strnad M; Espinosa-Bustos C; Salas CO
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794311
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents.
Dong J; Pan X; Wang J; Su P; Zhang L; Wei F; Zhang J
Eur J Med Chem; 2015 Aug; 101():780-9. PubMed ID: 26231079
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
[TBL] [Abstract][Full Text] [Related]
14. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Vrontaki E; Melagraki G; Voskou S; Phylactides MS; Mavromoustakos T; Kleanthous M; Afantitis A
Mini Rev Med Chem; 2017; 17(3):188-204. PubMed ID: 28143387
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W
Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429
[TBL] [Abstract][Full Text] [Related]
16. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
17. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
Liu L; Li X; Cheng Y; Wang L; Yang H; Li J; He S; Shuangjie Wu ; Yin Q; Xiang H
Eur J Med Chem; 2019 Feb; 164():304-316. PubMed ID: 30605829
[TBL] [Abstract][Full Text] [Related]
18. Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib.
Pan X; Dong J; Shao R; Su P; Shi Y; Wang J; He L
Bioorg Med Chem Lett; 2015 Oct; 25(19):4164-8. PubMed ID: 26298495
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel Bcr-Abl
Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
[TBL] [Abstract][Full Text] [Related]
20. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
